Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, today announced the merger of Isto Biologics, a portfolio company of TSCP and a global leader in regenerative and autologous therapies, and Advanced Biologics (Biologica Technologies). Terms of the transaction were not disclosed.
The merger will expand Isto’s growing portfolio of bone grafts and seamlessly integrate Advanced Biologics’ proprietary products alongside Influx™, Isto’s esteemed line of cortical fiber allografts.
“We are delighted to welcome the entire Advanced Biologics team to Isto Biologics,” said Donald Brown, CEO of Isto Biologics. “This merger brings together the best of both companies’ expertise and a shared commitment to help patients heal faster.”
Isto Biologics has maintained a commercial partnership with Advanced Biologics since 2020, catalyzed by the development of Isto’s Integrative Bone Matrix, SPARC™. SPARC™ is a novel inductive bone matrix that stemmed from Advanced Biologics’ proprietary tissue processing method used in their flagship product OsseoGEN. SPARC™ is known for its increased levels of osteoinductive, chemotactic, angiogenic and proliferative growth factors.
The integration of Advanced Biologics’ product commercialization initiatives into Isto’s growing allograft portfolio provides a unique opportunity to help patients heal fast and enable both customer bases to benefit from the broadened product.
“With this merger, our combined team now brings greater clinical expertise and deeper customer support to provide our surgeon champions with the best products available on the market,” said Amit Govil, President of Advanced Biologics.
“Over the past four years, our collaboration with Advanced Biologics has been impressive,” said Harry Holiday, Chairman of the Board at Isto Biologics and Managing Director at Thompson Street Capital Partners. “Investing in Advanced Biologics and embarking on this strategic combination amplifies both Isto’s and Advanced Biologics’ comprehensive biologics portfolios, paving a path forward for continued growth and patient healing.”
